We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Thermo Fisher Scientific

Thermo Fisher Scientific Inc. serves customers who are accelerating life sciences research, solving complex analytica... read more Featured Products: More products

Download Mobile App




Blood Test Predicts Prostate Tumor Resistance

By LabMedica International staff writers
Posted on 07 Sep 2017
Prostate cancer (PCa) is the most common cancer and the third leading cause of cancer death among European men. More...
In metastatic PCa progression from a hormone-sensitive state to castration resistance under androgen deprivation therapy marks the transition to the lethal phenotype of the disease.

Treatment resistance still poses a major challenge in metastatic castration-resistant PCa (mCRPC). Approximately one-third of patients show primary resistance to abiraterone and enzalutamide treatment without any decline in serum prostate-specific antigen (PSA) levels, and virtually all of the initial responders develop secondary resistance over time.

A team of scientists at the Technical University of Munich (Germany) and their colleagues analyzed blood samples from 85 patients with advanced stages of prostate cancer. Blood samples were collected in PAXgene blood RNA tubes within one week before treatment initiation. Total RNA was extracted from blood samples according to the manufacturer's instructions using the Qiagen PAXgene blood RNA kit.

A NanoDrop 1000 spectrophotometer was used for quantification and purity assessment of RNA samples. Complementary DNA (cDNA) was synthesized from 1 μg of RNA using qScript XLT SuperMix. Androgen receptor splice variant 7 (AR-V7) and AR full length (AR-FL) messenger RNA (mRNA} levels were simultaneously quantified in a dual color assay using custom primer and hydrolysis probe sets on a QX200 ddPCR system with automatic droplet generation.

The team was able to successfully demonstrate that approximately one fifth of the patients had large amounts of AR-V7 RNA in their blood which was an indication of large quantities of resistant tumor cells. It was exactly these patients who failed to respond to therapy with abiraterone and enzalutamide. They also had poorer prognoses during the subsequent course of their illness. Their tumors returned more quickly and they had shorter survival times than other patients.

Silvia Thöne, PhD, co-lead author of the study said, “Only minute amounts of RNA are needed in a sample for the test to work. Additionally, since AR-V7 RNA is present in every tumor cell that possesses the resistant receptors, it means that no tumor cells are slipping by undetected.” The study was published on August 14, 2017, in the journal European Urology.


Gold Member
Respiratory Syncytial Virus Test
OSOM® RSV Test
Collection and Transport System
PurSafe Plus®
Gold Member
Cardiovascular Risk Test
Metabolic Syndrome Array I & II
Blood Glucose Test Strip
AutoSense Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more

Immunology

view channel
Image: The CloneSeq-SV approach can allow researchers to study how cells within high-grade serous ovarian cancer change over time (Photo courtesy of MSK)

Blood Test Tracks Treatment Resistance in High-Grade Serous Ovarian Cancer

High-grade serous ovarian cancer (HGSOC) is often diagnosed at an advanced stage because it spreads microscopically throughout the abdomen, and although initial surgery and chemotherapy can work, most... Read more

Industry

view channel
Image: The collaboration aims to improve access to Hb variant testing with the Gazelle POC diagnostic platform (Photo courtesy of Hemex Health)

Terumo BCT and Hemex Health Collaborate to Improve Access to Testing for Hemoglobin Disorders

Millions of people worldwide living with sickle cell disease and other hemoglobin disorders experience delayed diagnosis and limited access to effective care, particularly in regions where testing is scarce.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.